Observation of short-term therapeutic and adverse effect of lentinan and gemcitabine plus cisplatin as the first-line treatment for advanced non-small cell lung cancer

Abstract

Abstract: AIM: To evaluate the short-term therapeutic and adverse effect of lentinan(LNT) and gemcitabine(GEM) plus cisplatin(DDP)(GP regimen)as the first-line treatment for advanced non-small cell lung cancer(NSCLC). METHODS: A total of 71 patients were randomly assigned to two regimens. 71 advanced NSCLC cases diagnosed by clinical pathology or cellular biopsy were divided into control group treated with GP regimen and observation group treated with lentinan and GP regimen. The usage of GP was gemcitabine 1000 mg/m²,d1,d8;cisplatin 25 mg/m², i.v.,d1-d3; for intravenous use in control group; based on the above,in observation group,lentinan was administered by 1 mg, twice a week intravenously.The chemotherapy interval was 21 days,and the clinical therapeutic and adverse effect were assessed after 2 to 4 cycles. RESULTS: Among 35 cases in observation group(LNT +GP group):13 patients had PR,19 patients had SD and 3 patients had PD.RR and DCR was 37.1%(13/35)and 91.4%(32/35)respectively. TTP was 6.8 months,MST was 12.3 months and the 1-year survival rate was 45.7%(16/35);while those of control group (GP group):13 patients had PR,18 patients had SD and 5 patients had PD. RR and DCR was 36.1%(13/36)and 86.1%(31/36)respectively. TTP was 6.5 months,MST was 11.6 months and the 1-year survival rate was 41.7%(15/36).The variance of short-term therapeutic effect had no statistic significance(P>0.05).The improve rate of Karnofsky Performance Status(KPS) was 77.1%(27/35) and 38.9%(14/36)for observation group and control group(P<0.05),respectively.The main side-effects of the two groups included hematologic toxicites,digestive tract reaction and hairloss.The incidence of Ⅲ/Ⅳ neutropenia was significantly less incurred in observation group than that in control group(14.3%/36.1%,P<0.05); The incidence of Ⅲ/Ⅳ nausea and vomiting was less incurred in observation group than that in control group(11.4%/19.4%, P>0.05).CONCLUSION: LNT combined with GP regimen as the first-line treatment for advanced NSCLC can ameliorate life quality,enhance efficacy and reduce side-effects.So lentinan can become an important remedy adjuvant of chemotherapy.

Key words: Non-small cell lung cancer, Lentinan, Gemcitabine, Cisplatin, Chemotherapy

CLC Number:

R734.2

ZHAO Wen-ying, CHEN Dong-yun, CHEN Jing-hua. Observation of short-term therapeutic and adverse effect of lentinan and gemcitabine plus cisplatin as the first-line treatment for advanced non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 71-77.

References

[1] 杨功焕. 中国人群死亡及其危险因素流行水平、趋势和分布[M]. 北京: 中国协和医科大学出版社,2005:75.
[2] Ahmedin J,Freddie B,Melissa M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[3] Bidoli P, Zilembo N, Cortinovis D,et al.Randomized phaseⅡthree-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Itanlian Trials in Medical Oncology study[J].Annals Oncology,2007,18(3):461-467.
[4] 王金万. 实体瘤的疗效评价标准//孙燕,石远凯. 临床肿瘤内科手册[M]. 5 版. 北京:人民卫生出版社,2007:152-153.
[5] 陈振东,戴金珠.肿瘤分期诊断及疗效评价//陈振东,秦凤展,秦叔逵. 肿瘤学概论[M].北京:人民军医出版社,2006:143.
[6] 孙燕. 抗肿瘤药物的近期和远期不良反应//孙燕,石远凯. 临床肿瘤内科手册[M]. 5 版. 北京:人民卫生出版社,2007:142-145.
[7] Non-Small Cell Lung Cancer Collaborative Group.Chemotherapy and supportive care versus supportive care alone for advanced non-small-cell lung cancer[J].Cochrane Database Syst Rev,2010,(5):CD007309.
[8] Ozkaya S,Findik S,Uzun O,et al . Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in patients with advanced non-small cell lung cancer[J]. Clin Med Circ Respirat Pulm Med,2008,2:27-34.
[9] 高广辉,周鑫莉,黄若凡,等. 铂类联合吉西他滨或长春瑞滨治疗晚期非小细胞肺癌的Meta分析[J]. 中国肺癌杂志,2009,12(1):38-43.
[10] Rabik CA, Dolan ME.Molecular mechanisms of resistance and toxicity associated with platinating agents[J].Cancer Treat Rev,2007,33(1): 9-23.
[11] Martin LP, Hamilton TC, Schider RJ.Platinum resistance: The role of DNA repair pathways[J].Clin Cancer Res,2008,14(5):1291-1295.
[12] Mini E,Nobili S,Caciagli B,et al.Cellular pharmacology of gemcitabine[J]. Ann Oncol,2006,17(Suppl 5):v7-v12.
[13] Rosell R, Cobo M, Isla D, et al.Pharmacogenomics and gemcitabine[J]. Ann Oncol,2006,17(Suppl 5):v13-v16.
[14] Achanta G,Pelicano H,Feng L,et al.Interaction of p53 and DNA-PK in response to nucleoside analogues:potential role as a sensor complex for DNA damage[J].Cancer Res,2001,61(24):8723-8729.
[15] Hasturk S,Hatabay N,Ece F,et al.Gemcitabine,vinorelbine,and Cisplatin in the treatment of advanced non small cell lung cancer[J]. Am J Clin Oncol,2009,32(3):280-285.
[16] 赵文英,吉兆宁.顺铂加吉西他滨与顺铂加长春瑞滨一线治疗晚期非小细胞肺癌的对照研究[J].中国临床药理学与治疗学,2006,11(12):1408-1411.
[17] 张玉,束永前. 吉西他滨联合顺铂一线治疗晚期非小细胞肺癌50例临床观察[J].南京医科大学学报:自然科学版,2009,(6):860-862.
[18] McWilliams A,Lam B,Sutedja T.Early proximal lung cancer diagnosis and treatment[J].Eur Respir J,2009,33(3):656-665.
[19] Chihara G,Maeda Y,Hamuro J,et al.Inhibition of mouse Sarcoma 180 by polysaccharides from Lentinus edodes (Berk) Sing[J].Nature,1969,222(5194):687-688.
[20] 丛阳,黄敏.香菇多糖抗肿瘤的基础研究及临床应用进展[J].大连医科大学学报,2010,32(4):465-469.
[21] Markova N,Kussovski V,Drandarska I,et al.Protective activity of lentinan in experimental tuberculosis[J].lnt Immunopharmaco1,2003, 3(10/ll):1557-1562.
[22] Kimura Y,Iijima S,Kato T,et al.TS-1 and lentinan combination immunochemotherapy for advanced or recurrent gastric cancer:a preliminary report[J].Gan To Kagaka Ryoho,2003,30(11):1791-1793.
[23] Wang W,Dai X,Ouyang X.Efficacy of Lentinan combined with chemotherapy in advanced non-small cell lung cancer[J].Zhongguo Fei Ai Za Zhi,2006,9(1):78-81.
[24] Mushiake H,Tsunoda T,Nukatsuka M,et al.Dendirtic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo[J].Cancer Immunol Immunother,2005,54(2):120-128.
[25] Wang JL,Bi Z,Zou JW,et al.Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma[J].Mol Med Report,2012,5(3):745-748.
[26] Higashi D,Seki K,Ishibashi Y,et al.The effect of lentinan combination therapy for unresectable advanced gastric cancer[J].Anticancer Res,2012,32(6):2365-2368.
[27] 柏建岭,刘薇,于浩. 香菇多糖联合化疗治疗肺癌近期疗效和免疫功能的评估[J].临床肿瘤学杂志,2008,13(8):724-729.